Cognate BioServices was a premier commercial-ready global CDMO specializing in cell and gene therapy manufacturing, acquired by Charles River Laboratories in 2021 for approximately $875 million. The company, along with its gene therapy division Cobra Biologics, provided cell therapy manufacturing, plasmid DNA production, and viral vector capabilities across US and European facilities. It is now integrated into Charles River's cell and gene therapy CDMO solutions.
Cell therapy manufacturing, gene therapy CDMO, viral vector production, plasmid DNA manufacturing
1 site worldwide
No certifications on file yet.
No reviews available yet.
No documents available.